Acadia Pharmaceuticals Inc’s recently made public that its Director Brege Laura unloaded Company’s shares for reported $0.31 million on Jun 04 ’25. In the deal valued at $21.78 per share,14,446 shares were sold. As a result of this transaction, Brege Laura now holds 15,095 shares worth roughly $0.36 million.
Then, LAURA BREGE bought 14,446 shares, generating $314,638 in total proceeds.
Before that, Kihara James sold 4,000 shares. Acadia Pharmaceuticals Inc shares valued at $90,000 were divested by the PRINCIPAL ACCOUNTING OFFICER at a price of $22.50 per share. As a result of the transaction, Kihara James now holds 20,395 shares, worth roughly $0.49 million.
Deutsche Bank upgraded its Acadia Pharmaceuticals Inc [ACAD] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Hold”‘ rating. Guggenheim also remained covering ACAD and has decreased its forecast on January 03, 2025 with a “Neutral” recommendation from previously “Buy” rating.
Price Performance Review of ACAD
On Monday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock jump 2.17% to $24.04. Over the last five days, the stock has gained 6.28%. Acadia Pharmaceuticals Inc shares have risen nearly 26.39% since the year began. Nevertheless, the stocks have risen 31.01% over the past one year.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2025-07-15, dropping by -3.96 million shares to a total of 11.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 15.44 million shares. There was a decline of -34.48%, which implies that there is a negative sentiment for the stock.
